Otsuka acquired CAN10, a Phase 1 anti-IL1RAP antibody for inflammatory/autoimmune diseases, from Swedish biotech Cantargia. $33M upfront plus up to $580M in development, regulatory and commercial milestones (total $613M) plus tiered royalties up to double digits. Closed September 11, 2025. Post-close, Otsuka took over development: the Phase 1 first-in-human study (NCT06143371, sponsor now Otsuka Pharmaceutical Development & Commercialization) completed on November 10, 2025, evaluating CAN10 in healthy subjects and mild-to-moderate plaque psoriasis patients.
Key facts
AnnouncedSep 11, 2025
ClosedSep 11, 2025
Deal value$613M
Deal typeAsset Purchase
Therapeutic areaAutoimmune and inflammatory diseases (psoriasis initial)
IndicationsAutoimmune and inflammatory diseases (psoriasis initial)